A Back-to-Front Fragment-Based Drug Design Search Strategy Targeting the DFG-Out Pocket of Protein Tyrosine Kinases

被引:28
作者
Iwata, Hidehisa [1 ]
Oki, Hideyuki [1 ]
Okada, Kengo [1 ]
Takagi, Terufumi [1 ]
Tawada, Michiko [1 ]
Miyazaki, Yasushi [1 ]
Imamura, Shinichi [2 ]
Hori, Akira [2 ]
Lawson, J. David [3 ]
Hixon, Mark S. [3 ]
Kimura, Hiroyuki [1 ]
Miki, Hiroshi [1 ]
机构
[1] Takeda Pharmaceut Co Ltd, Discovery Res Labs, Fujisawa, Kanagawa 2518555, Japan
[2] Takeda Pharmaceut Co Ltd, Oncol Drug Discovery Unit, Div Pharmaceut Res, Fujisawa, Kanagawa 2518555, Japan
[3] Takeda Calif Inc, San Diego, CA 92121 USA
关键词
back-to-front; FBDD; DFG-out; VEGFR2; phosphorylation; Yonetani-Theorell Plot; LEAD DISCOVERY; INHIBITORS; BINDING; PHOSPHORYLATION;
D O I
10.1021/ml3000403
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We present a straightforward process for the discovery of novel back pocket-binding fragment molecules against protein tyrosine kinases. The approach begins by screening against the nonphosphorylated target kinase with subsequent counterscreening of hits against the phosphorylated enzyme. Back pocket-binding fragments are inactive against the phosphorylated kinase. Fragment molecules are of insufficient size to span both regions of the ATP binding pocket; thus, the outcome is binary (back pocket-binding or hinge-binding). Next, fragments with the appropriate binding profile are assayed in combination with a known hinge-binding fragment and subsequently with a known back pocket-binding fragment. Confirmation of back pocket-binding by Yonetani-Theorell plot analysis progresses candidate fragments to crystallization trials. The method is exemplified by a fragment screening campaign against vascular endothelial growth factor receptor 2, and a novel back pocket-binding fragment is presented.
引用
收藏
页码:342 / 346
页数:5
相关论文
共 23 条
[1]   Activation loop phosphorylation and catalysis in protein kinases: Is there functional evidence for the autoinhibitor model? [J].
Adams, JA .
BIOCHEMISTRY, 2003, 42 (03) :601-607
[2]   Kinase array design, back to front: Biaryl amides [J].
Baldwin, Ian ;
Bamborough, Paul ;
Haslam, Claudine G. ;
Hunjan, Suchete S. ;
Longstaff, Tim ;
Mooney, Christopher J. ;
Patel, Shila ;
Quinn, Jo ;
Somers, Don O. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (19) :5285-5289
[3]   Oncogenic kinase signalling [J].
Blume-Jensen, P ;
Hunter, T .
NATURE, 2001, 411 (6835) :355-365
[4]   A rule of three for fragment-based lead discovery? [J].
Congreve, M ;
Carr, R ;
Murray, C ;
Jhoti, H .
DRUG DISCOVERY TODAY, 2003, 8 (19) :876-877
[5]   Recent developments in fragment-based drug discovery [J].
Congreve, Miles ;
Chessari, Gianni ;
Tisi, Dominic ;
Woodhead, Andrew J. .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (13) :3661-3680
[6]   Transforming fragments into candidates: small becomes big in medicinal chemistry [J].
de Kloe, Gerdien E. ;
Bailey, David ;
Leurs, Rob ;
de Esch, Iwan J. P. .
DRUG DISCOVERY TODAY, 2009, 14 (13-14) :630-646
[7]   Do enthalpy and entropy distinguish first in class from best in class? [J].
Freire, Ernesto .
DRUG DISCOVERY TODAY, 2008, 13 (19-20) :869-874
[8]   Autoregulatory mechanisms in protein-tyrosine kinases [J].
Hubbard, SR ;
Mohammadi, M ;
Schlessinger, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (20) :11987-11990
[9]   The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: Its role in cell growth and disease [J].
Hunter, T .
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 1998, 353 (1368) :583-605
[10]   Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: Comparison of binding to non-phosphorylated and phosphorylated VEGFR2 [J].
Iwata, Hidehisa ;
Imamura, Shinichi ;
Hori, Akira ;
Hixon, Mark S. ;
Kimura, Hiroyuki ;
Miki, Hiroshi .
BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (18) :5342-5351